Re-challenge therapy with chemotherapy and panitumumab in metastatic colorectal cancer patients treated with an anti-EGFR therapy in 1st line treatment: a phase II multicentre study.

drug protocol number
19-504
drug sponsor
King Abdullah Medical City, Holy Capital
drug study
PANITUMUMAB
drug trial site
KAMC
drug status
Ongoing
drug phase